Aâ imaging in aging, alzheimer’s disease and other neurodegenerative conditions

Pet and Spect in Neurology

Volumn , Issue , 2014, Pages 213-254

  Villemagne, Victor L ^a   Fodero Tavoletti, Michelle ^b   Yates, Paul ^a   Masters, Colin L ^b   Rowe, Christopher C ^b  

^a AUSTIN HEALTH   (Australia)

^b FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84940991246     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-642-54307-4_10     Document Type: Chapter

References (361)

1. Agdeppa ED, Kepe V, Liu J et al (2001a) Binding characteristics of radiofluorinated 6-dialkylamino- 2-naphthylethylidene derivatives as positron emission tomography imaging probes for beta- amyloid plaques in Alzheimer’s disease. J Neurosci 21:RC189
2. Agdeppa ED, Kepe V, Shoghi-Jadid K et al (2001b) In vivo and in vitro labeling of plaques and tangles in the brain of an Alzheimer’s disease patient: A case study. J Nucl Med 42:65
3. Aizenstein HJ, Nebes RD, Saxton JA et al (2008) Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol 65:1509-1517
4. Albert MS, Dekosky ST, Dickson D et al (2011) The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 7:270-279
5. Apostolova LG, Hwang KS, Andrawis JP et al (2010) 3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects. Neurobiol Aging 31:1284-1303
6. Archer HA, Edison P, Brooks DJ et al (2006) Amyloid load and cerebral atrophy in Alzheimer’s disease: An 11C-PIB positron emission tomography study. Ann Neurol 60:145-147
7. Armstrong RA, Cairns NJ, Lantos PL (2000) Beta-amyloid deposition in the temporal lobe of patients with dementia with Lewy bodies: Comparison with non-demented cases and Alzheimer’s disease. Dement Geriatr Cogn Disord 11:187-192
8. Arnold SE, Han LY, Clark CM et al (2000) Quantitative neurohistological features of frontotem- poral degeneration. Neurobiol Aging 21:913-919
9. Backman L, Jones S, Berger AK et al (2005) Cognitive impairment in preclinical Alzheimer’s disease: A meta-analysis. Neuropsychology 19:520-531
10. Bacskai BJ, Frosch MP, Freeman SH et al (2007) Molecular imaging with Pittsburgh Compound B confirmed at autopsy: A case report. Arch Neurol 64:431-434
11. Barrio JR, Huang SC, Cole G et al (1999) PET imaging of tangles and plaques in Alzheimer disease with a highly hydrophobic probe. J Label Compd Radiopharm 42:S194-S195
12. Barthel H, Gertz HJ, Dresel S et al (2011) Cerebral amyloid-beta PET with florbetaben ((18)F) in patients with Alzheimer’s disease and healthy controls: A multicentre phase 2 diagnostic study. Lancet Neurol 10:424-435
13. Basun H, Bogdanovic N, Ingelsson M et al (2008) Clinical and neuropathological features of the arctic APP gene mutation causing early-onset alzheimer disease. Arch Neurol 65:499-505
14. Bateman RJ, Munsell LY, Morris JC et al (2006) Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat Med 12:856-861
15. Bateman RJ, Xiong C, Benzinger TL et al (2012) Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N Engl J Med 367:795-804
16. Bauer M, Langer O, Dal-Bianco P et al (2006) A positron emission tomography microdosing study with a potential antiamyloid drug in healthy volunteers and patients with Alzheimer’s disease. Clin Pharmacol Ther 80:216-227
17. Beach TG, Monsell SE, Phillips LE et al (2012) Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010. J Neuropathol Exp Neurol 71:266-273
18. Becker JA, Hedden T, Carmasin J et al (2011) Amyloid-beta associated cortical thinning in clinically normal elderly. Ann Neurol 69:1032-1042
19. Berg L, McKeel DW Jr, Miller JP et al (1998) Clinicopathologic studies in cognitively healthy aging and Alzheimer’s disease: Relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Arch Neurol 55:326-335
20. Blennow K, Zetterberg H, Minthon L et al (2007) Longitudinal stability of CSF biomarkers in Alzheimer’s disease. Neurosci Lett 419:18-22
21. Bourgeat P, Chetelat G, Villemagne VL et al (2010) Beta-amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia. Neurology 74:121-127
22. Braak H, Braak E (1997) Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging 18:351-357
23. Bresjanac M, Smid LM, Vovko TD et al (2003) Molecular-imaging probe 2-(1-[6-[(2-fluoroethyl) (methyl) amino]-2-naphthyl]ethylidene) malononitrile labels prion plaques in vitro. J Neurosci 23:8029-8033
24. Buckley C, Ikonomovic M, Smith A et al (2012) Flutemetamol F 18 injection PET images reflect brain beta-amyloid levels. Alzheimers Dement 8:P90
25. Buckner RL, Snyder AZ, Shannon BJ et al (2005) Molecular, structural, and functional characterization of Alzheimer’s disease: Evidence for a relationship between default activity, amyloid, and memory. J Neurosci 25:7709-7717
26. Buckner RL, Andrews-Hanna JR, Schacter DL (2008) The brain’s default network: Anatomy, function, and relevance to disease. Ann N Y Acad Sci 1124:1-38
27. Burack, MA, Hartlein, J, Flores, HP et al (2010) In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia. Neurology 74:77-84
28. Cairns NJ, Bigio EH, Mackenzie IR et al (2007) Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: Consensus of the consortium for frontotemporal lobar degeneration. Acta Neuropathol 114:5-22
29. Cairns NJ, Ikonomovic MD, Benzinger T et al (2009) Absence of Pittsburgh Compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: A case report. Arch Neurol 66:1557-1562
30. Camus V, Payoux P, Barre L et al (2012) Using PET with (18)F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment. Eur J Nucl Med Mol Imaging 39:621-631
31. Cappai R, White AR (1999) Amyloid beta. Int J Biochem Cell Biol 31:885-889
32. Carter SF, Scholl M, Almkvist O et al (2012) Evidence for astrocytosis in prodromal Alzheimer disease provided by 11C-deuterium-L-deprenyl: A multitracer PET paradigm combining 11C-Pittsburgh Compound B and 18F-FDG. J Nucl Med 53:37-46
33. Chang CY, Silverman DH (2004) Accuracy of early diagnosis and its impact on the management and course of Alzheimer’s disease. Expert Rev Mol Diagn 4:63-69
34. Chetelat G, Desgranges B, de la Sayette V et al (2003) Dissociating atrophy and hypometabolism impact on episodic memory in mild cognitive impairment. Brain 126:1955-1967
35. Chetelat G, Eustache F, Viader F et al (2005) FDG-PET measurement is more accurate than neuropsychological assessments to predict global cognitive deterioration in patients with mild cognitive impairment. Neurocase 11:14-25
36. Chetelat G, Villemagne VL, Bourgeat P et al (2010a) Relationship between atrophy and beta- amyloid deposition in Alzheimer disease. Ann Neurol 67:317-324
37. Chetelat G, Villemagne VL, Pike KE et al (2010b) Larger temporal volume in elderly with high versus low beta-amyloid deposition. Brain 133:3349-3358
38. Chetelat G, Villemagne VL, Villain N et al (2012) Accelerated cortical atrophy in cognitively normal elderly with high beta-amyloid deposition. Neurology 78:477-484
39. Choi SR, Golding G, Zhuang Z et al (2009) Preclinical properties of 18F-AV-45: A PET agent for Abeta plaques in the brain. J Nucl Med 50:1887-1894
40. Clark CM, Davatzikos C, Borthakur A et al (2008) Biomarkers for early detection of Alzheimer pathology. Neurosignals 16:11-18
41. Clark CM, Schneider JA, Bedell BJ et al (2011) Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA 305:275-283
42. Clark CM, Pontecorvo MJ, Beach TG et al (2012) Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-beta plaques: A prospective cohort study. Lancet Neurol 11:669-678
43. Cohen AD, Price JC, Weissfeld LA et al (2009) Basal cerebral metabolism may modulate the cognitive effects of Abeta in mild cognitive impairment: An example of brain reserve. J Neurosci 29:14770-14778
44. Cohen AD, Rabinovici GD, Mathis CA et al (2012) Using Pittsburgh Compound B for in vivo PET imaging of fibrillar amyloid-beta. Adv Pharmacol 64:27-81
45. Coleman R.E., (2005) Positron emission tomography diagnosis of Alzheimer’s disease. Neuroimaging Clin N Am 15:837-846
46. Cordonnier C (2010) Brain microbleeds. Pract Neurol 10:94-100
47. Cselenyi Z, Jonhagen ME, Forsberg A et al (2012) Clinical validation of 18F-AZD4694, an amyloid-beta-specific PET radioligand. J Nucl Med 53:415-424
48. Cummings JL, Vinters HV, Cole GM et al (1998) Alzheimer’s disease: Etiologies, pathophysiology, cognitive reserve, and treatment opportunities. Neurology 51:S2-S17;
49. Davies L., Wolska B., Hilbich C., et al (1988) A4 amyloid protein deposition and the diagnosis of Alzheimer’s disease: Prevalence in aged brains determined by immunocytochemistry compared with conventional neuropathologic techniques. Neurology 38:1688-1693
50. de Leon MJ, DeSanti S, Zinkowski R et al (2006) Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment. Neurobiol Aging 27:394-401
51. de Leon MJ, Mosconi L, Blennow K et al (2007) Imaging and CSF studies in the preclinical diagnosis of Alzheimer’s disease. Ann N Y Acad Sci 1097:114-145
52. DeKosky ST, Ikonomovic MD, Styren SD et al (2002) Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol 51:145-155
53. Deshpande A, Mina E, Glabe C et al (2006) Different conformations of amyloid beta induce neurotoxicity by distinct mechanisms in human cortical neurons. J Neurosci 26:6011-6018
54. Devanand DP, Jacobs DM, Tang MX et al (1997) The course of psychopathologic features in mild to moderate Alzheimer disease. Arch Gen Psychiatry 54:257-263
55. Dhollander I, Nelissen N, Van Laere K et al (2011) In vivo amyloid imaging in cortical superficial siderosis. J Neurol Neurosurg Psychiatry 82:469-471
56. Dierksen GA, Skehan ME, Khan MA et al (2010) Spatial relation between microbleeds and amyloid deposits in amyloid angiopathy. Ann Neurol 68:545-548
57. Doraiswamy PM, Sperling RA, Coleman RE et al (2012) Amyloid-beta assessed by florbetapir F 18 PET and 18-month cognitive decline: A multicenter study. Neurology 79:1636-1644
58. Drago V, Babiloni C, Bartres-Faz D et al (2011) Disease tracking markers for Alzheimer’s disease at the prodromal (MCI) stage. J Alzheimers Dis 26(Suppl 3):159-199
59. Driscoll I, Zhou Y, An Y et al (2011) Lack of association between (11)C-PiB and longitudinal brain atrophy in non-demented older individuals. Neurobiol Aging 32:2123-2130
60. Drzezga A (2010) Amyloid-plaque imaging in early and differential diagnosis of dementia. Ann Nucl Med 24:55-66
61. Drzezga A, Lautenschlager N, Siebner H et al (2003) Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer’s disease: A PET follow-up study. Eur J Nucl Med Mol Imaging 30:1104-1113
62. Drzezga A, Grimmer T, Riemenschneider M et al (2005) Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET. J Nucl Med 46:1625-1632
63. Drzezga A, Grimmer T, Henriksen G et al (2008) Imaging of amyloid plaques and cerebral glucose metabolism in semantic dementia and Alzheimer’s disease. Neuroimage 39:619-633
64. Drzezga A, Becker JA, Van Dijk KR et al (2011) Neuronal dysfunction and disconnection of cortical hubs in non-demented subjects with elevated amyloid burden. Brain 134: 1635-1646
65. Dubois B, Feldman HH, Jacova C et al (2010) Revising the definition of Alzheimer’s disease: A new lexicon. Lancet Neurol 9:1118-1127
66. Eckert A, Keil U, Marques CA et al (2003) Mitochondrial dysfunction, apoptotic cell death, and Alzheimer’s disease. Biochem Pharmacol 66:1627-1634
67. Edison P, Archer HA, Hinz R et al (2007) Amyloid, hypometabolism, and cognition in Alzheimer disease: An [11C]PIB and [18F]FDG PET study. Neurology 68:501-508
68. Edison P, Archer HA, Gerhard A et al (2008a) Microglia, amyloid, and cognition in Alzheimer’s disease: An [11C](R)PK11195-PET and [11C]PIB-PET study. Neurobiol Dis 32:412-419
69. Edison P, Rowe CC, Rinne JO et al (2008b) Amyloid load in Parkinson’s disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. J Neurol Neurosurg Psychiatry 79:1331-1338
70. Engler H, Forsberg A, Almkvist O et al (2006) Two-year follow-up of amyloid deposition in patients with Alzheimer’s disease. Brain 129:2856-2866
71. Engler H, Santillo AF, Wang SX et al (2008) In vivo amyloid imaging with PET in frontotemporal dementia. Eur J Nucl Med Mol Imaging 35:100-106
72. Fagan AM, Holtzman DM (2010) Cerebrospinal fluid biomarkers of Alzheimer’s disease. Biomark Med 4:51-63
73. Fagan AM, Mintun MA, Mach RH et al (2006) Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta(42) in humans. Ann Neurol 59:512-519
74. Fagan AM, Roe CM, Xiong C et al (2007) Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol 64:343-349
75. Fagan AM, Mintun MA, Shah AR et al (2009) Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer’s disease. EMBO Mol Med 1:371-380
76. Farrer LA, Cupples LA, Haines JL et al (1997) Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer disease meta analysis consortium. JAMA 278:1349-1356
77. Feldman HH, Maia LF, Mackenzie IR et al (2008) Superficial siderosis: A potential diagnostic marker of cerebral amyloid angiopathy in Alzheimer disease. Stroke 39:2894-2897
78. Fleisher AS, Chen K, Liu X et al (2011) Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Arch Neurol 68:1404-1411
79. Fodero-Tavoletti MT, Smith DP, McLean CA et al (2007) In vitro characterization of Pittsburgh Compound-B binding to Lewy bodies. J Neurosci 27:10365-10371
80. Fodero-Tavoletti MT, Mulligan RS, Okamura N et al (2009a) In vitro characterisation of BF227 binding to alpha-synuclein/Lewy bodies. Eur J Pharmacol 617:54-58
81. Fodero-Tavoletti MT, Rowe CC, McLean CA et al (2009b) Characterization of PiB binding to white matter in Alzheimer disease and other dementias. J Nucl Med 50:198-204
82. Fodero-Tavoletti MT, Okamura N, Furumoto S et al (2011) 18F-THK523: A novel in vivo tau imaging ligand for Alzheimer’s disease. Brain 134:1089-1100
83. Formaglio M, Costes N, Seguin J et al (2011) In vivo demonstration of amyloid burden in posterior cortical atrophy: A case series with PET and CSF findings. J Neurol 258:1841-1851
84. Forman MS, Mufson EJ, Leurgans S et al (2007) Cortical biochemistry in MCI and Alzheimer disease: Lack of correlation with clinical diagnosis. Neurology 68:757-763
85. Forsberg A, Engler H, Almkvist O et al (2008) PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 29:1456-1465
86. Forsberg A, Almkvist O, Engler H et al (2010) High PIB retention in Alzheimer’s disease is an early event with complex relationship with CSF biomarkers and functional parameters. Curr Alzheimer Res 7:56-66
87. Forster S, Grimmer T, Miederer I et al (2012) Regional expansion of hypometabolism in Alzheimer’s disease follows amyloid deposition with temporal delay. Biol Psychiatry 71:792-797
88. Foster ER, Campbell MC, Burack MA et al (2010) Amyloid imaging of Lewy body-associated disorders. Mov Disord 25:2516-2523
89. Frisoni GB, Fox NC, Jack CR Jr et al (2010) The clinical use of structural MRI in Alzheimer disease. Nat Rev Neurol 6:67-77
90. Furst AJ, Rabinovici GD, Rostomian AH et al (2012) Cognition, glucose metabolism and amyloid burden in Alzheimer’s disease. Neurobiol Aging 33(2):215-225
91. Furukawa K, Okamura N, Tashiro K et al (2011) PET imaging with BF-227 in dementia with Lewy bodies. Alzheimers Dement 7:S12-S13
92. Gomez-Isla T, West HL, Rebeck GW et al (1996) Clinical and pathological correlates of apolipo- protein E epsilon 4 in Alzheimer’s disease. Ann Neurol 39:62-70
93. Gomperts SN, Rentz DM, Moran E et al (2008) Imaging amyloid deposition in Lewy body diseases. Neurology 71:903-910
94. Grimmer T, Riemenschneider M, Forstl H et al (2009) Beta amyloid in Alzheimer’s disease: Increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid. Biol Psychiatry 65:927-934
95. Grimmer T, Tholen S, Yousefi BH et al (2010) Progression of cerebral amyloid load is associated with the apolipoprotein E epsilon4 genotype in Alzheimer’s disease. Biol Psychiatry 68:879-884
96. Gurol ME, Dierksen G, Betensky R et al (2012) Predicting sites of new hemorrhage with amyloid imaging in cerebral amyloid angiopathy. Neurology 79:320-326
97. Halliday G, Hely M, Reid W et al (2008) The progression of pathology in longitudinally followed patients with Parkinson’s disease. Acta Neuropathol 115:409-415
98. Hampel H, Blennow K, Shaw LM et al (2010) Total and phosphorylated tau protein as biological markers of Alzheimer’s disease. Exp Gerontol 45:30-40
99. Hansson O, Zetterberg H, Buchhave P et al (2007) Prediction of Alzheimer’s disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment. Dement Geriatr Cogn Disord 23:316-320
100. Hardy J (1997) Amyloid, the presenilins and Alzheimer’s disease. Trends Neurosci 20:154-159
101. Herholz K (1995) FDG PET and differential diagnosis of dementia. Alzheimer Dis Assoc Disord 9:6-16
102. Hill AF, Joiner S, Wadsworth JD et al (2003) Molecular classification of sporadic Creutzfeldt- Jakob disease. Brain 126:1333-1346
103. Hodges JR, Patterson K (2007) Semantic dementia: A unique clinicopathological syndrome. Lancet Neurol 6:1004-1014
104. Hyman B.T., (2011) Amyloid-dependent and amyloid-independent stages of Alzheimer disease. Arch Neurol 68:1062-1064
105. Ikonomovic MD, Abrahamson EE, Isanski BA et al (2007) Superior frontal cortex cholinergic axon density in mild cognitive impairment and early Alzheimer disease. Arch Neurol 64:1312-1317
106. Ikonomovic MD, Klunk WE, Abrahamson EE et al (2008) Post-mortem correlates of in vivo PiB- PET amyloid imaging in a typical case of Alzheimer’s disease. Brain 131:1630-1645
107. Ikonomovic MD, Klunk WE, Abrahamson EE et al (2011) Precuneus amyloid burden is associated with reduced cholinergic activity in Alzheimer disease. Neurology 77:39-47
108. Ikonomovic MD, Abrahamson EE, Price JC et al (2012) Early AD pathology in a [C-11]PiB- negative case: A PiB-amyloid imaging, biochemical, and immunohistochemical study. Acta Neuropathol 123:433-447
109. Inayathullah M, Teplow DB (2011) Structural dynamics of the DeltaE22 (Osaka) familial Alzheimer’s disease-linked amyloid beta-protein. Amyloid 18:98-107
110. Isacson O, Seo H, Lin L et al (2002) Alzheimer’s disease and Down’s syndrome: Roles of APP, trophic factors and ACh. Trends Neurosci 25:79-84
111. Jack CR Jr, Lowe VJ, Senjem ML et al (2008a) 11C PiB and structural MRI provide complementary information in imaging of Alzheimer’s disease and amnestic mild cognitive impairment. Brain 131:665-680
112. Jack CR Jr, Weigand SD, Shiung MM et al (2008b) Atrophy rates accelerate in amnestic mild cognitive impairment. Neurology 70:1740-1752
113. Jack CR Jr, Lowe VJ, Weigand SD et al (2009) Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer’s disease: Implications for sequence of pathological events in Alzheimer’s disease. Brain 132:1355-1365
114. Jack CR Jr, Knopman DS, Jagust WJ et al (2010) Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol 9:119-128
115. Jagust W (2009) Mapping brain beta-amyloid. Curr Opin Neurol 22:356-361
116. Jagust WJ (2011) Amyloid imaging: Liberal or conservative? Let the data decide. Arch Neurol 68:1377-1378
117. Jagust W, Reed B, Mungas D et al (2007) What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia? Neurology 69:871-877
118. Jellinger K (1990) Morphology of Alzheimer disease and related disorders. In: Maurer K et al (eds) Alzheimer disease: Epidemiology, neuropathology, neurochemistry, and clinics. Springer, Berlin, pp 61-77
119. Jellinger KA (2010) Con: Can neuropathology really confirm the exact diagnosis? Alzheimers Res Ther 2:11
120. Jellinger KA, Attems J (2005) Prevalence and pathogenic role of cerebrovascular lesions in Alzheimer disease. J Neurol Sci 229-230:37-41
121. Jellinger KA, Bancher C (1998) Neuropathology of Alzheimer’s disease: A critical update. J Neural Transm Suppl 54:77-95
122. Johansson A, Savitcheva I, Forsberg A et al (2008) [(11)C]-PIB imaging in patients with Parkinson’s disease: Preliminary results. Parkinsonism Relat Disord 14:345-347
123. Johnson KA (2006) Amyloid imaging of Alzheimer’s disease using Pittsburgh Compound B. Curr Neurol Neurosci Rep 6:496-503
124. Johnson N, Davis T, Bosanquet N (2000) The epidemic of Alzheimer’s disease. How can we manage the costs? Pharmacoeconomics 18:215-223
125. Johnson KA, Gregas M, Becker JA et al (2007) Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann Neurol 62:229-234
126. Johnson AE, Jeppsson F, Sandell J et al (2009) AZD2184: A radioligand for sensitive detection of beta-amyloid deposits. J Neurochem 108:1177-1186
127. Josephs KA, Holton JL, Rossor MN et al (2004) Frontotemporal lobar degeneration and ubiquitin immunohistochemistry. Neuropathol Appl Neurobiol 30:369-373
128. Jureus A, Swahn BM, Sandell J et al (2010) Characterization of AZD4694, a novel fluorinated Abeta plaque neuroimaging PET radioligand. J Neurochem 114:784-794
129. Kadir A, Marutle A, Gonzalez D et al (2011) Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer’s disease. Brain 134:301-317
130. Kalaitzakis ME, Walls AJ, Pearce RK et al (2011) Striatal Abeta peptide deposition mirrors dementia and differentiates DLB and PDD from other parkinsonian syndromes. Neurobiol Dis 41:377-384
131. Kambe T, Motoi Y, Ishii K et al (2010) Posterior cortical atrophy with [11C] Pittsburgh Compound B accumulation in the primary visual cortex. J Neurol 257:469-471
132. Karran E, Mercken M, De Strooper B (2011) The amyloid cascade hypothesis for Alzheimer’s disease: An appraisal for the development of therapeutics. Nat Rev Drug Discov 10:698-712
133. Kemppainen NM, Aalto S, Wilson IA et al (2007) PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment. Neurology 68:1603-1606
134. Kemppainen NM, Aalto S, Karrasch M et al (2008) Cognitive reserve hypothesis: Pittsburgh Compound B and fluorodeoxyglucose positron emission tomography in relation to education in mild Alzheimer’s disease. Ann Neurol 63:112-118
135. Kennedy AM, Frackowiak RS, Newman SK et al (1995) Deficits in cerebral glucose metabolism demonstrated by positron emission tomography in individuals at risk of familial Alzheimer’s disease. Neurosci Lett 186:17-20
136. Khachaturian ZS (1985) Diagnosis of Alzheimer’s disease. Arch Neurol 42:1097-1105
137. Kikuchi A, Takeda A, Okamura N et al (2010) In vivo visualization of alpha-synuclein deposition by carbon-11-labelled 2-[2-(2-dimethylaminothiazol-5-yl)ethenyl]-6-[2-(fluoro)ethoxy]ben- zoxazole positron emission tomography in multiple system atrophy. Brain 133:1772-1778
138. Klunk WE (2011) Amyloid imaging as a biomarker for cerebral beta-amyloidosis and risk prediction for Alzheimer dementia. Neurobiol Aging 32(Suppl 1):S20-S36
139. Klunk WE, Wang Y, Huang GF et al (2001) Uncharged thioflavin-T derivatives bind to amyloid- beta protein with high affinity and readily enter the brain. Life Sci 69:1471-1484
140. Klunk WE, Wang Y, Huang GF et al (2003) The binding of 2-(4’-methylaminophenyl)benzothia- zole to postmortem brain homogenates is dominated by the amyloid component. J Neurosci 23:2086-2092
141. Klunk WE, Engler H, Nordberg A et al (2004) Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann Neurol 55:306-319
142. Klunk WE, Lopresti BJ, Ikonomovic MD et al (2005) Binding of the positron emission tomography tracer Pittsburgh Compound-B reflects the amount of amyloid-beta in Alzheimer’s disease brain but not in transgenic mouse brain. J Neurosci 25:10598-10606
143. Klunk WE, Price JC, Mathis CA et al (2007) Amyloid deposition begins in the striatum of prese- nilin-1 mutation carriers from two unrelated pedigrees. J Neurosci 27:6174-6184
144. Klunk W, Cohen AD, Bi W et al (2012) Why we need two cutoffs for amyloid imaging: Early versus Alzheimer’s-like amyloid-positivity. Alzheimers Dement 8:P453-P454
145. Knudsen KA, Rosand J, Karluk D et al (2001) Clinical diagnosis of cerebral amyloid angiopathy: Validation of the Boston criteria. Neurology 56:537-539
146. Koeppe RA, Gilman S, Junck L et al (2008) Differentiating Alzheimer’s disease from dementia with Lewy bodies and Parkinson’s disease with (+)-[11C]dihydrotetrabenazine positron emission tomography. Alzheimers Dement 4:S67-S76
147. Koivunen J, Pirttila T, Kemppainen N et al (2008a) PET amyloid ligand [C]PIB uptake and cerebrospinal fluid beta-amyloid in mild cognitive impairment. Dement Geriatr Cogn Disord 26:378-383
148. Koivunen J, Verkkoniemi A, Aalto S et al (2008b) PET amyloid ligand [11C]PIB uptake shows predominantly striatal increase in variant Alzheimer’s disease. Brain 131:1845-1853
149. Kuczynski B, Reed B, Mungas D et al (2008) Cognitive and anatomic contributions of metabolic decline in Alzheimer disease and cerebrovascular disease. Arch Neurol 65:650-655
150. Kudo Y (2006) Development of amyloid imaging PET probes for an early diagnosis of Alzheimer’s disease. Minim Invasive Ther Allied Technol 15:209-213
151. Kudo Y, Okamura N, Furumoto S et al (2007) 2-(2-[2-Dimethylaminothiazol-5-yl]Ethenyl)-6- (2-[Fluoro]Ethoxy)Benzoxazole: A novel PET agent for in vivo detection of dense amyloid plaques in Alzheimer’s disease patients. J Nucl Med 48:553-561
152. Landau SM, Harvey D, Madison CM et al (2011) Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol Aging 32(7):1207-1218
153. Landt J, D’Abrera JC, Holland AJ et al (2011) Using positron emission tomography and carbon 11-labeled Pittsburgh Compound B to image brain fibrillar beta-amyloid in adults with Down syndrome: Safety, acceptability, and feasibility. Arch Neurol 68:890-896
154. Larson EB, Edwards JK, O’Meara E et al (1996) Neuropathologic diagnostic outcomes from a cohort of outpatients with suspected dementia. J Gerontol A Biol Sci Med Sci 51(suppl 6):M313-M318
155. Laruelle M, Slifstein M, Huang Y (2003) Relationships between radiotracer properties and image quality in molecular imaging of the brain with positron emission tomography. Mol Imaging Biol 5:363-375
156. Leinonen V, Alafuzoff I, Aalto S et al (2008) Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B. Arch Neurol 65:1304-1309
157. Leuner K, Hauptmann S, Abdel-Kader R et al (2007) Mitochondrial dysfunction: The first domino in brain aging and Alzheimer’s disease? Antioxid Redox Signal 9:1659-1675
158. LeVine H., 3rd (1999) Quantification of beta-sheet amyloid fibril structures with thioflavin T. Methods Enzymol 309:274-284
159. Levine H., Walker L.C., (2010a) Molecular polymorphism of Abeta in Alzheimer’s disease. Neurobiol Aging 31(4):542-548
160. Levine H., Walker L.C., (2010b) Molecular polymorphism of Abeta in Alzheimer’s disease. Neurobiol Aging 31:542-548
161. Leyton CE, Villemagne VL, Savage S et al (2011) Subtypes of progressive aphasia: Application of the international consensus criteria and validation using {beta}-amyloid imaging. Brain 134:3030-3043
162. Liberski PP (2004) Amyloid plaques in transmissible spongiform encephalopathies (prion diseases). Folia Neuropathol 42(Suppl B):109-119
163. Lin KS, Debnath ML, Mathis CA et al (2009) Synthesis and beta-amyloid binding properties of rhenium 2-phenylbenzothiazoles. Bioorg Med Chem Lett 19:2258-2262
164. Lister-James J, Pontecorvo MJ, Clark C et al (2011) Florbetapir f-18: A histopathologically validated beta-amyloid positron emission tomography imaging agent. Semin Nucl Med 41:300-304
165. Lockhart A, Ye L, Judd DB et al (2005) Evidence for the presence of three distinct binding sites for the thioflavin T class of Alzheimer’s disease PET imaging agents on beta-amyloid peptide fibrils. J Biol Chem 280:7677-7684
166. Lockhart A, Lamb JR, Osredkar T et al (2007) PIB is a non-specific imaging marker of amyloid- beta (Abeta) peptide-related cerebral amyloidosis. Brain 130:2607-2615
167. Lopresti BJ, Klunk WE, Mathis CA et al (2005) Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: A comparative analysis. J Nucl Med 46:1959-1972
168. Lowe VJ, Kemp BJ, Jack CR Jr et al (2009) Comparison of 18F-FDG and PiB PET in cognitive impairment. J Nucl Med 50:878-886
169. Mackenzie IR, Foti D, Woulfe J et al (2008) Atypical frontotemporal lobar degeneration with ubiquitin-positive, TDP-43-negative neuronal inclusions. Brain 131:1282-1293
170. Maeda J, Ji B, Irie T et al (2007) Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer’s disease enabled by positron emission tomography. J Neurosci 27:10957-10968
171. Maetzler W., Reimold M., Liepelt I., et al (2008) [11C]PIB binding in Parkinson’s disease dementia. Neuroimage 39:1027-1033
172. Maetzler W, Liepelt I, Reimold M et al (2009) Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics. Neurobiol Dis 34:107-112
173. Maezawa I, Hong HS, Liu R et al (2008) Congo red and thioflavin-T analogs detect Abeta oligomers. J Neurochem 104:457-468
174. Majocha RE, Reno JM, Friedland RP et al (1992) Development of a monoclonal antibody specific for B/A4 amyloid in Alzheimer’s disease brain for application to in vivo imaging of amyloid angiopathy. J Nucl Med 33:2184-2189
175. Marchant NL, Reed BR, Decarli CS et al (2012) Cerebrovascular disease, beta-amyloid, and cognition in aging. Neurobiol Aging 33(5):1006.e25-36
176. Maruyama M, Maeda J, Ji B et al (2009) In-vivo optical and PET detections of fibrillar tau lesions in a mouse model of tauopathies. Alzheimers Dement 55:P209-P210
177. Masliah E, Rockenstein E, Veinbergs I et al (2001) Beta-amyloid peptides enhance alpha- synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer’s disease and Parkinson’s disease. Proc Natl Acad Sci USA 98: 12245-12250
178. Masters CL (2005) Neuropathology of Alzheimer’s disease. In: Burns A et al (eds) Dementia, 3rd edn. Hodder Arnold, London, pp 393-407
179. Masters CL, Beyreuther K (2005) The neuropathology of Alzheimer’s disease in the year 2005. In: Beal MF et al (eds) Neurodegenerative diseases: Neurobiology, pathogenesis and therapeutics. Cambridge University Press, Cambridge, pp 433-440
180. Masters CL, Beyreuther K (2006) Alzheimer’s centennial legacy: Prospects for rational therapeutic intervention targeting the Abeta amyloid pathway. Brain 129:2823-2839
181. Masters CL, Simms G, Weinman NA et al (1985) Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A 82:4245-4249
182. Masters CL, Cappai R, Barnham KJ et al (2006) Molecular mechanisms for Alzheimer’s disease: Implications for neuroimaging and therapeutics. J Neurochem 97:1700-1725
183. Mathis CA, Bacskai BJ, Kajdasz ST et al (2002) A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain. Bioorg Med Chem Lett 12:295-298
184. Mathis CA, Klunk WE, Price JC et al (2005) Imaging technology for neurodegenerative diseases: Progress toward detection of specific pathologies. Arch Neurol 62:196-200
185. Mathis CA, Lopresti BJ, Klunk WE (2007) Impact of amyloid imaging on drug development in Alzheimer’s disease. Nucl Med Biol 34:809-822
186. Mattsson N, Zetterberg H, Hansson O et al (2009) CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 302:385-393
187. Mattsson N, Andreasson U, Persson S et al (2011) The Alzheimer’s Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement 7:386-395.
188. Mawuenyega KG, Sigurdson W, Ovod V et al (2010) Decreased clearance of CNS beta-amyloid in Alzheimer’s disease. Science 330:1774
189. McKeith I.G., Mosimann U.P., (2004) Dementia with Lewy bodies and Parkinson’s disease. Parkinsonism Relat Disord 10(Suppl 1):S15-S18
190. McKeith IG, Dickson DW, Lowe J et al (2005) Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium. Neurology 65:1863-1872
191. McKhann GM, Knopman DS, Chertkow H et al (2011) The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 7:263-269
192. McLean CA, Cherny RA, Fraser FW et al (1999) Soluble pool of AB amyloid as a determinant of severity of neurodegeneration in Alzheimer’s disease. Ann Neurol 46:860-866
193. Michaelis ML, Dobrowsky RT, Li G (2002) Tau neurofibrillary pathology and microtubule stability. J Mol Neurosci 19:289-293
194. Mielke R, Herholz K, Grond M et al (1992) Differences of regional cerebral glucose metabolism between presenile and senile dementia of Alzheimer type. Neurobiol Aging 13:93-98
195. Mintun MA, Larossa GN, Sheline YI et al (2006) [11C]PIB in a nondemented population: Potential antecedent marker of Alzheimer disease. Neurology 67:446-452
196. Mirra SS, Heyman A, McKeel D et al (1991) The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer’s disease. Neurology 41:479-486
197. Montine TJ, Phelps CH, Beach TG et al (2012) National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: A practical approach. Acta Neuropathol 123:1-11
198. Mormino EC, Kluth JT, Madison CM et al (2009) Episodic memory loss is related to hippocampal- mediated beta-amyloid deposition in elderly subjects. Brain 132:1310-1323
199. Mormino EC, Brandel MG, Madison CM et al (2012) Not quite PIB-positive, not quite PIB-negative: Slight PIB elevations in elderly normal control subjects are biologically relevant. Neuroimage 59:1152-1160
200. Morris JC (2012) Revised criteria for mild cognitive impairment may compromise the diagnosis of Alzheimer disease dementia. Arch Neurol 69:700-708. doi:10.1001/archneurol.2011.3152
201. Morris JC, Price AL (2001) Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer’s disease. J Mol Neurosci 17:101-118
202. Morris JC, Kimberly A, Quaid K et al (2005) Role of biomarkers in studies of presymptomatic Alzheimer’s disease. Alzheimers Dement 1:145-151
203. Morris JC, Roe CM, Grant EA et al (2009) Pittsburgh Compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol 66:1469-1475
204. Morris JC, Roe CM, Xiong C et al (2010) APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol 67:122-131
205. Mortimer JA (1997) Brain reserve and the clinical expression of Alzheimer’s disease. Geriatrics 52(Suppl 2):S50-S53
206. Mosconi L, Perani D, Sorbi S et al (2004) MCI conversion to dementia and the APOE genotype: A prediction study with FDG-PET. Neurology 63:2332-2340
207. Mosconi L, De Santi S, Li Y et al (2006a) Visual rating of medial temporal lobe metabolism in mild cognitive impairment and Alzheimer’s disease using FDG-PET. Eur J Nucl Med Mol Imaging 33:210-221
208. Mosconi L, Sorbi S, de Leon MJ et al (2006b) Hypometabolism exceeds atrophy in presymptom- atic early-onset familial Alzheimer’s disease. J Nucl Med 47:1778-1786
209. Mott RT, Dickson DW, Trojanowski JQ et al (2005) Neuropathologic, biochemical, and molecular characterization of the frontotemporal dementias. J Neuropathol Exp Neurol 64:420-428
210. Naslund J, Haroutunian V, Mohs R et al (2000) Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA 283:1571-1577
211. Nelissen N, Van Laere K, Thurfjell L et al (2009) Phase 1 study of the Pittsburgh Compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease. J Nucl Med 50:1251-1259
212. Neumann M, Sampathu DM, Kwong LK et al (2006) Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314:130-133
213. Neumann M, Rademakers R, Roeber S et al (2009) A new subtype of frontotemporal lobar degeneration with FUS pathology. Brain 132:2922-2931
214. Newberg AB, Wintering NA, Plossl K et al (2006) Safety, biodistribution, and dosimetry of 123I-IMPY: A novel amyloid plaque-imaging agent for the diagnosis of Alzheimer’s disease. J Nucl Med 47:748-754
215. Ng S, Villemagne VL, Berlangieri S et al (2007a) Visual assessment versus quantitative assessment of 1 1C-PIB PET and 18F-FDG PET for detection of Alzheimer’s disease. J Nucl Med 48:547-552
216. Ng SY, Villemagne VL, Masters CL et al (2007b) Evaluating atypical dementia syndromes using positron emission tomography with carbon 11 labeled Pittsburgh Compound B. Arch Neurol 64:1140-1144
217. Noda A, Murakami Y, Nishiyama S et al (2008) Amyloid imaging in aged and young macaques with [11C]PIB and [18F]FDDNP. Synapse 62:472-475
218. Nordberg A (2004) PET imaging of amyloid in Alzheimer’s disease. Lancet Neurol 3:519-527
219. Nordberg A (2007) Amyloid imaging in Alzheimer’s disease. Curr Opin Neurol 20:398-402
220. Nyberg S, Jonhagen ME, Cselenyi Z et al (2009) Detection of amyloid in Alzheimer’s disease with positron emission tomography using [11C]AZD2184. Eur J Nucl Med Mol Imaging 36:1859-1863
221. O’Brien J, Ames D, Burns A (2000) Dementia, 2nd edn. Arnold, London
222. O’Brien JT, Colloby S, Fenwick J et al (2004) Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies. Arch Neurol 61:919-925
223. Ojida A, Sakamoto T, Inoue MA et al (2009) Fluorescent BODIPY-based Zn(II) complex as a molecular probe for selective detection of neurofibrillary tangles in the brains of Alzheimer’s disease patients. J Am Chem Soc 131:6543-6548
224. Okamura N, Suemoto T, Shimadzu H et al (2004) Styrylbenzoxazole derivatives for in vivo imaging of amyloid plaques in the brain. J Neurosci 24:2535-2541
225. Okamura N, Suemoto T, Furumoto S et al (2005) Quinoline and benzimidazole derivatives: Candidate probes for in vivo imaging of tau pathology in Alzheimer’s disease. J Neurosci 25:10857-10862
226. kamura N, Shiga Y, Furumoto S et al (2010) In vivo detection of prion amyloid plaques using [(11)C]BF-227 PET. Eur J Nucl Med Mol Imaging 37:934-941
227. Okello A, Edison P, Archer HA et al (2009a) Microglial activation and amyloid deposition in mild cognitive impairment: A PET study. Neurology 72:56-62
228. 11C-PIB PET study. Neurology 73:754-760
229. Ong K, Villemagne VL, Lamngon N et al (2010) Assessment of Ap deposition in mild cognitive impairment with 18F-Florbetaben. Alzheimer Dement 6:S26
230. Opazo C, Luza S, Villemagne VL et al (2006) Radioiodinated clioquinol as a biomarker for beta- amyloid: Zn complexes in Alzheimer’s disease. Aging Cell 5:69-79
231. Ossenkoppele R, van Berckel BN, Prins ND (2011) Amyloid imaging in prodromal Alzheimer’s disease. Alzheimers Res Ther 3:26 Ossenkoppele R, Tolboom N, Foster-Dingley JC et al (2012) Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PET. Eur J Nucl Med Mol Imaging 39:990-1000
232. Ostrowitzki S, Deptula D, Thurfjell L et al (2012) Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol 69(2):198-207
233. Petersen RC (2000) Mild cognitive impairment: Transition between aging and Alzheimer’s disease. Neurologia 15:93-101
234. Petersen RC, Smith GE, Ivnik RJ et al (1995) Apolipoprotein E status as a predictor of the development of Alzheimer’s disease in memory-impaired individuals. JAMA 273:1274-1278
235. Petersen RC, Smith GE, Waring SC et al (1999) Mild cognitive impairment: Clinical characterization and outcome. Arch Neurol 56:303-308
236. Pettersen JA, Sathiyamoorthy G, Gao FQ et al (2008) Microbleed topography, leukoaraiosis, and cognition in probable Alzheimer disease from the Sunnybrook dementia study. Arch Neurol 65:790-795
237. Phelps ME (2000) PET: The merging of biology and imaging into molecular imaging. J Nucl Med 41:661-681
238. Pike V.W., (2009) PET radiotracers: Crossing the blood-brain barrier and surviving metabolism. Trends Pharmacol Sci 30:431-440
239. Pike KE, Savage G, Villemagne VL et al (2007) Beta-amyloid imaging and memory in nondemented individuals: Evidence for preclinical Alzheimer’s disease. Brain 130:2837-2844
240. Pike KE, Ellis KA, Villemagne VL et al (2011) Cognition and beta-amyloid in preclinical Alzheimer’s disease: Data from the AIBL study. Neuropsychologia 49:2384-2390
241. Pletnikova O, West N, Lee MK et al (2005) Abeta deposition is associated with enhanced cortical a-synuclein lesions in Lewy body diseases. Neurobiol Aging 26:1183-1192
242. Price JL, Morris JC (1999) Tangles and plaques in nondemented aging and “preclinical” Alzheimer’s disease. Ann Neurol 45:358-368
243. Price JC, Klunk WE, Lopresti BJ et al (2005) Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab 25:1528-1547
244. Qiu C, Xu W, Fratiglioni L (2010) Vascular and psychosocial factors in Alzheimer’s disease: Epidemiological evidence toward intervention. J Alzheimers Dis 20:689-697
245. Qu W, Kung MP, Hou C et al (2007a) Novel styrylpyridines as probes for SPECT imaging of amyloid plaques. J Med Chem 50:2157-2165
246. Qu W, Kung MP, Hou C et al (2007b) Radioiodinated aza-diphenylacetylenes as potential SPECT imaging agents for beta-amyloid plaque detection. Bioorg Med Chem Lett 17:3581-3584
247. Rabinovici GD, Jagust WJ (2009) Amyloid imaging in aging and dementia: Testing the amyloid hypothesis in vivo. Behav Neurol 21:117-128
248. Rabinovici GD, Miller BL (2010) Frontotemporal lobar degeneration: Epidemiology, pathophysiology, diagnosis and management. CNS Drugs 24:375-398
249. 11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration. Neurology 68:1205-1212
250. Rabinovici GD, Jagust WJ, Furst AJ et al (2008) Abeta amyloid and glucose metabolism in three variants of primary progressive aphasia. Ann Neurol 64:388-401
251. Rabinovici GD, Furst AJ, Alkalay A et al (2010) Increased metabolic vulnerability in early- onset alzheimer’s disease is not related to amyloid burden. Brain 133:512-528
252. Rabinovici GD, Rosen HJ, Alkalay A et al (2011) Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD. Neurology 77:2034-2042
253. Reiman EM, Caselli RJ, Yun LS et al (1996) Preclinical evidence of Alzheimer’s disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med 334:752-758
254. Reiman EM, Chen K, Liu X et al (2009) Fibrillar amyloid-p burden in cognitively normal people at 3 levels of genetic risk for Alzheimer’s disease. Proc Natl Acad Sci U S A 106:6820-6825
255. Remes AM, Laru L, Tuominen H et al (2008) Carbon 11-labeled Pittsburgh Compound B positron emission tomographic amyloid imaging in patients with APP locus duplication. Arch Neurol 65:540-544
256. Rentz DM, Locascio JJ, Becker JA et al (2010) Cognition, reserve, and amyloid deposition in normal aging. Ann Neurol 67:353-364
257. Resende R, Pereira C, Agostinho P et al (2007) Susceptibility of hippocampal neurons to Abeta peptide toxicity is associated with perturbation of Ca2+ homeostasis. Brain Res 1143:11-21
258. Resnick SM, Lamar M, Driscoll I (2007) Vulnerability of the orbitofrontal cortex to age-associated structural and functional brain changes. Ann N Y Acad Sci 1121:562-575
259. Resnick SM, Sojkova J, Zhou Y et al (2010) Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [11C]PiB. Neurology 74:807-815
260. Riekse RG, Leverenz JB, McCormick W et al (2004) Effect of vascular lesions on cognition in Alzheimer’s disease: A community-based study. J Am Geriatr Soc 52:1442-1448
261. 1 1C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer’s disease treated with bapineuzumab: A phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 9:363-372
262. Roder S, Danober L, Pozza MF et al (2003) Electrophysiological studies on the hippocampus and prefrontal cortex assessing the effects of amyloidosis in amyloid precursor protein 23 transgenic mice. Neuroscience 120:705-720
263. Roe CM, Mintun MA, D’Angelo G et al (2008) Alzheimer disease and cognitive reserve: Variation of education effect with carbon 11-labeled Pittsburgh Compound B uptake. Arch Neurol 65:1467-1471
264. Rosen RF, Walker LC, Levine H, 3rd (2011) PIB binding in aged primate brain: Enrichment of high-affinity sites in humans with Alzheimer’s disease. Neurobiol Aging 32:223-234
265. Rosendorff C, Beeri MS, Silverman JM (2007) Cardiovascular risk factors for Alzheimer’s disease. Am J Geriatr Cardiol 16:143-149
266. Rossor MN, Kennedy AM, Frackowiak RS (1996) Clinical and neuroimaging features of familial Alzheimer’s disease. Ann N Y Acad Sci 777:49-56
267. Rowe CC, Villemagne VL (2011) Brain amyloid imaging. J Nucl Med 52:1733-1740
268. Rowe C.C., Ng S., Ackermann U., et al (2007) Imaging beta-amyloid burden in aging and dementia. Neurology 68:1718-1725
269. Rowe CC, Ackerman U, Browne W et al (2008) Imaging of amyloid beta in Alzheimer’s disease with (18)F-BAY94-9172, a novel PET tracer: Proof of mechanism. Lancet Neurol 7:129-135
270. Rowe CC, Ellis KA, Rimajova M et al (2010) Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging 31:1275-1283
271. Sabbagh MN, Fleisher A, Chen K et al (2011) Positron emission tomography and neuropathologic estimates of fibrillar amyloid-beta in a patient with Down syndrome and Alzheimer disease. Arch Neurol 68:1461-1466
272. Sabbagh M, Seibyl J, Akatsu H et al (2012) Multicentre phase 3 trial on florbetaben for beta-amyloid brain PET in Alzheimer’s disease. Alzheimers Dement 8:P90
273. Sair H.I., Doraiswamy P.M., Petrella J.R., (2004) In vivo amyloid imaging in Alzheimer’s disease. Neuroradiology 46:93-104
274. Salmon E, Sadzot B, Maquet P et al (1994) Differential diagnosis of Alzheimer’s disease with PET. J Nucl Med 35:391-398
275. Scheltens P., Rockwood K., (2011) How golden is the gold standard of neuropathology in dementia? Alzheimers Dement 7:486-489
276. Scholl M, Almqvist O, Graff C et al (2011) Amyloid imaging in members of a family harbouring the Arctic mutation. Alzheimers Dement 7(Suppl 1):303
277. Schulz-Schaeffer WJ (2010) The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson’s disease and Parkinson’s disease dementia. Acta Neuropathol 120:131-143
278. Serdons K, Verduyckt T, Cleynhens J et al (2007) Synthesis and evaluation of a (99m)Tc-BAT- phenylbenzothiazole conjugate as a potential in vivo tracer for visualization of amyloid beta. Bioorg Med Chem Lett 17:6086-6090
279. Serdons K, Terwinghe C, Vermaelen P et al (2009a) Synthesis and evaluation of (18)F-Labeled 2-Phenylbenzothiazoles as positron emission tomography imaging agents for amyloid plaques in Alzheimer’s disease. J Med Chem 52:1428-1437
280. Serdons K, Verduyckt T, Vanderghinste D et al (2009b) Synthesis of18F-labelled 2-(4’-fluorophenyl)- 1,3-benzothiazole and evaluation as amyloid imaging agent in comparison with [11C]PIB. Bioorg Med Chem Lett 19:602-605
281. Shaw LM, Korecka M, Clark CM et al (2007) Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics. Nat Rev Drug Discov 6:295-303
282. Shih WJ, Markesbery WR, Clark DB et al (1987) Iodine-123 HIPDM brain imaging findings in subacute spongiform encephalopathy (Creutzfeldt-Jakob disease). J Nucl Med 28: 1484-1487
283. Shoghi-Jadid K, Small GW, Agdeppa ED et al (2002) Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am J Geriatr Psychiatry 10:24-35
284. Siderowf A, Xie SX, Hurtig H et al (2010) CSF amyloid beta 1-42 predicts cognitive decline in Parkinson disease. Neurology 75:1055-1061
285. Silverman DH, Small GW, Chang CY et al (2001) Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. JAMA 286:2120-2127
286. Silverman DH, Cummings JL, Small GW et al (2002) Added clinical benefit of incorporating 2-deoxy-2-[18F]fluoro-D-glucose with positron emission tomography into the clinical evaluation of patients with cognitive impairment. Mol Imaging Biol 4:283-293
287. Small GW, Mazziotta JC, Collins MT et al (1995) Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. JAMA 273:942-947
288. Small G.W., Agdeppa E.D., Kepe V., et al (2002) In vivo brain imaging of tangle burden in humans. J Mol Neurosci 19:323-327
289. Small GW, Kepe V, Ercoli LM et al (2006) PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med 355:2652-2663
290. Small BJ, Gagnon E, Robinson B (2007) Early identification of cognitive deficits: Preclinical Alzheimer’s disease and mild cognitive impairment. Geriatrics 62:19-23
291. Smith EE, Egorova S, Blacker D et al (2008) Magnetic resonance imaging white matter hyperintensities and brain volume in the prediction of mild cognitive impairment and dementia. Arch Neurol 65:94-100
292. Snowden J, Neary D, Mann D (2007) Frontotemporal lobar degeneration: Clinical and pathological relationships. Acta Neuropathol 114:31-38
293. Sojkova J, Resnick SM (2011) In vivo human amyloid imaging. Curr Alzheimer Res 8:366-372
294. Sojkova J, Driscoll I, Iacono D et al (2011a) In vivo fibrillar beta-amyloid detected using [11C]PiB positron emission tomography and neuropathologic assessment in older adults. Arch Neurol 68:232-240
295. Sojkova J, Zhou Y, An Y et al (2011b) Longitudinal patterns of beta-amyloid deposition in nondemented older adults. Arch Neurol 68:644-649
296. Song PJ, Bernard S, Sarradin P et al (2008) IMPY, a potential beta-amyloid imaging probe for detection of prion deposits in scrapie-infected mice. Nucl Med Biol 35:197-201
297. Sperling R., Johnson K., (2010) Pro: Can biomarkers be gold standards in Alzheimer’s disease? Alzheimers Res Ther 2:17
298. Sperling RA, Laviolette PS, O’Keefe K et al (2009) Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron 63:178-188
299. Sperling RA, Aisen PS, Beckett LA et al (2011a) Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 7:280-292
300. Sperling R.A, Jack C.R., Jr., Aisen P.S., (2011b) Testing the right target and right drug at the right stage. Sci Transl Med 3:111-133
301. Sperling RA, Jack CR Jr, Black SE et al (2011c) Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s Association Research Roundtable Workgroup. Alzheimers Dement 7:367-385
302. Sperling RA, Johnson KA, Doraiswamy PM et al (2012) Amyloid deposition detected with flor- betapir F 18 ((18)F-AV-45) is related to lower episodic memory performance in clinically normal older individuals. Neurobiol Aging 34(3):822-831
303. Stern Y (2002) What is cognitive reserve? Theory and research application of the reserve concept. J Int Neuropsychol Soc 8:448-460
304. Storandt M., Head D., Fagan A.M., et al (2012) Toward a multifactorial model of Alzheimer disease. Neurobiol Aging 33:2262-2271
305. Strozyk D, Blennow K, White LR et al (2003) CSF Abeta 42 levels correlate with amyloid- neuropathology in a population-based autopsy study. Neurology 60:652-656
306. Sunderland T, Gur RE, Arnold SE (2005) The use of biomarkers in the elderly: Current and future challenges. Biol Psychiatry 58:272-276
307. Sundgren-Andersson AK, Svensson SPS, Swahn BM et al (2009) AZD4694: Fluorinated Positron Emission Tomography (PET) radioligand for detection of beta-amyloid deposits. Alzheimers Dement 5:P267-P268
308. Suo Z, Wu M, Citron BA et al (2004) Abnormality of G-protein-coupled receptor kinases at prodromal and early stages of Alzheimer’s disease: An association with early beta-amyloid accumulation. J Neurosci 24:3444-3452
309. Sur C, Zeng Z, Hostetler E et al (2010) In vitro characterization of MK-3328: A novel fluorinated positron emission tomography tracer for beta-amyloid plaques. Alzheimers Dement 6:S40
310. Taniguchi S, McDonagh AM, Pickering-Brown SM et al (2004) The neuropathology of frontotem- poral lobar degeneration with respect to the cytological and biochemical characteristics of tau protein. Neuropathol Appl Neurobiol 30:1-18
311. Tenovuo O, Kemppainen N, Aalto S et al (2008) Posterior cortical atrophy: A rare form of dementia with in vivo evidence of amyloid-beta accumulation. J Alzheimers Dis 15:351-355
312. Thal DR, Del Tredici K, Braak H (2004) Neurodegeneration in normal brain aging and disease. Sci Aging Knowl Environ 2004:pe26
313. Thal LJ, Kantarci K, Reiman EM et al (2006) The role of biomarkers in clinical trials for Alzheimer disease. Alzheimer Dis Assoc Disord 20:6-15
314. Thompson PW, Ye L, Morgenstern JL et al (2009) Interaction of the amyloid imaging tracer FDDNP with hallmark Alzheimer’s disease pathologies. J Neurochem 109:623-630
315. Thurfjell L, Lotjonen J, Lundqvist R et al (2012) Combination of biomarkers: Pet [F]Flutemetamol imaging and structural MRI in dementia and mild cognitive impairment. Neurodegener Dis 10:246-249
316. Tolboom N, van der Flier WM, Yaqub M et al (2009a) Relationship of cerebrospinal fluid markers to 11C-PiB and 18F-FDDNP binding. J Nucl Med 50:1464-1470
317. 11C-PIB and 18F-FDDNP PET. J Nucl Med 50:191-197
318. Tomiyama T, Nagata T, Shimada H et al (2008) A new amyloid beta variant favoring oligomerization in Alzheimer’s-type dementia. Ann Neurol 63:377-387
319. Tosun D, Schuff N, Mathis CA et al (2011) Spatial patterns of brain amyloid-beta burden and atrophy rate associations in mild cognitive impairment. Brain 134:1077-1088
320. Trojanowski JQ (2002) Emerging Alzheimer’s disease therapies: Focusing on the future. Neurobiol Aging 23:985-990
321. Tucker AM, Stern Y (2011) Cognitive reserve in aging. Curr Alzheimer Res 8:354-360
322. Vandenberghe R, Thurfjell L, Van Laere K et al (2010a) Comparison between cerebellum and pons as reference regions for quantification of the amyloid imaging agents [18F]flutemetamol and [11C]PIB. In: Proceedings of the human amyloid imaging Toronto, Canada, p. 42
323. Vandenberghe R, Van Laere K, Ivanoiu A, et al (2010b) 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial. Ann Neurol 68: 319-329
324. Venneti S, Lopresti BJ, Wiley CA (2006) The peripheral benzodiazepine receptor (Translocator protein 18kDa) in microglia: From pathology to imaging. Prog Neurobiol 80:308-322
325. Verhoeff NP, Wilson AA, Takeshita S et al (2004) In-vivo imaging of Alzheimer disease beta- amyloid with [11C]SB-13 PET. Am J Geriatr Psychiatry 12:584-595
326. Vernooij MW, van der Lugt A, Ikram MA et al (2008) Prevalence and risk factors of cerebral microbleeds: The Rotterdam Scan Study. Neurology 70:1208-1214
327. Villain N, Chetelat G, Grassiot B et al (2012) Regional dynamics of amyloid-beta deposition in healthy elderly, mild cognitive impairment and Alzheimer’s disease: A voxelwise PiB-PET longitudinal study. Brain 135:2126-2139
328. Villemagne VL, Rowe CC (2010) Amyloid ligands for dementia. PET Clin 5:33-53
329. Villemagne VL, Rowe CC, Macfarlane S et al (2005) Imaginem oblivionis: The prospects of neuroimaging for early detection of Alzheimer’s disease. J Clin Neurosci 12:221-230
330. Villemagne VL, Cappai R, Barnham KJ et al (2006) The Ap centric pathway of Alzheimer’s disease. In: Barrow CJ, Small BJ (eds) Abeta peptide and Alzheimer’s disease. Springer, London, pp 5-32
331. Villemagne VL, Fodero-Tavoletti MT, Pike KE et al (2008a) The ART of loss: Ap imaging in the evaluation of Alzheimer’s disease and other dementias. Mol Neurobiol 38:1-15
332. Villemagne VL, Pike KE, Darby D et al (2008b) Ap deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer’s disease. Neuropsychologia 46:1688-1697
333. Villemagne VL, Ataka S, Mizuno T et al (2009a) High striatal amyloid beta-peptide deposition across different autosomal Alzheimer disease mutation types. Arch Neurol 66:1537-1544
334. Villemagne VL, McLean CA, Reardon K et al (2009b) 11C-PiB PET studies in typical sporadic Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry 80:998-1001
335. Villemagne VL, Pike K, Pejoska S et al (2010) 11C-PiB PET ABri imaging in Worster-Drought syndrome (familial British dementia): A case report. J Alzheimers Dis 19:423-428
336. Villemagne VL, Ong K, Mulligan RS et al (2011a) Amyloid imaging with 18F-florbetaben in Alzheimer disease and other dementias. J Nucl Med 52:1210-1217
337. Villemagne VL, Pike KE, Chetelat G et al (2011b) Longitudinal assessment of Ap and cognition in aging and Alzheimer disease. Ann Neurol 69:181-192
338. Villemagne V.L., Furumoto S., Fodero-Tavoletti M.T., et al (2012a) In vivo tau imaging in Alzheimer’s disease and other dementias. Alzheimers Dement 8:P9
339. Villemagne V.L., Mulligan R.S., Pejoska S., et al (2012c) Comparison of (11)C-PiB and (18) F-florbetaben for Ap imaging in ageing and Alzheimer’s disease. Eur J Nucl Med Mol Imaging 39:983-989
340. Villemagne VL, Okamura N, Pejoska S et al (2012d) Differential diagnosis in Alzheimer’s disease and dementia with Lewy bodies via VMAT2 and amyloid imaging. Neurodegener Dis 10:161-165
341. Viswanathan A, Rocca WA, Tzourio C (2009) Vascular risk factors and dementia: How to move forward? Neurology 72:368-374
342. Vlassenko AG, Mintun MA, Xiong C et al (2011) Amyloid-beta plaque growth in cognitively normal adults: Longitudinal [11C] Pittsburgh Compound B data. Ann Neurol 70:857-861
343. Wahlund LO, Blennow K (2003) Cerebrospinal fluid biomarkers for disease stage and intensity in cognitively impaired patients. Neurosci Lett 339:99-102
344. Walker LC, Rosen RF, Levine H 3rd (2008) Diversity of Abeta deposits in the aged brain: A window on molecular heterogeneity? Rom J Morphol Embryol 49:5-11
345. Weller RO, Preston SD, Subash M et al (2009) Cerebral amyloid angiopathy in the aetiology and immunotherapy of Alzheimer disease. Alzheimers Res Ther 1:6
346. Wermke M, Sorg C, Wohlschlager AM et al (2008) A new integrative model of cerebral activation, deactivation and default mode function in Alzheimer’s disease. Eur J Nucl Med Mol Imaging 35(Suppl 1):S12-S24
347. Wiley CA, Lopresti BJ, Venneti S et al (2009) Carbon 11-labeled Pittsburgh Compound B and carbon 11-labeled (R)-PK11195 positron emission tomographic imaging in Alzheimer disease. Arch Neurol 66:60-67
348. Winblad B, Palmer K, Kivipelto M et al (2004) Mild cognitive impairment-beyond controversies, towards a consensus: Report of the International Working Group on Mild Cognitive Impairment. J Intern Med 256:240-246
349. Wolk DA, Price JC, Saxton JA et al (2009) Amyloid imaging in mild cognitive impairment subtypes. Ann Neurol 65:557-568
350. Wolk DA, Grachev ID, Buckley C et al (2011) Association between in vivo fluorine 18-labeled flutemetamol amyloid positron emission tomography imaging and in vivo cerebral cortical histopathology. Arch Neurol 68:1398-1403
351. Wolk DA, Price JC, Madeira C et al (2012a) Amyloid imaging in dementias with atypical presentation. Alzheimers Dement 8:389-398
352. Wolk DA, Zhang Z, Boudhar S et al (2012b) Amyloid imaging in Alzheimer’s disease: Comparison of florbetapir and Pittsburgh Compound-B positron emission tomography. J Neurol Neurosurg Psychiatry 83:923-926
353. Wong DF, Rosenberg PB, Zhou Y et al (2010) In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18). J Nucl Med 51:913-920
354. Wong DF, Moghekar AR, Rigamonti D et al (2013) An In vivo evaluation of cerebral cortical amyloid with [(18)F]flutemetamol using positron emission tomography compared with parietal biopsy samples in living normal pressure hydrocephalus patients. Mol Imaging Biol 15(2):230-237
355. Yates PA, Sirisriro R, Villemagne VL et al (2011) Cerebral microhemorrhage and brain {beta}- amyloid in aging and Alzheimer disease. Neurology 77:48-54
356. Ye L, Morgenstern JL, Gee AD et al (2005) Delineation of positron emission tomography imaging agent binding sites on beta-amyloid peptide fibrils. J Biol Chem 280:23599-23604
357. Ye L, Velasco A, Fraser G et al (2008) In vitro high affinity alpha-synuclein binding sites for the amyloid imaging agent PIB are not matched by binding to Lewy bodies in postmortem human brain. J Neurochem 105:1428-1437
358. Yee S, Mathis C, Klunk W et al (2007) Optimal time window for standardized uptake ratio as a simplified measure of PIB retention. J Nucl Med 48:404
359. Yokokura M, Mori N, Yagi S et al (2011) In vivo changes in microglial activation and amyloid deposits in brain regions with hypometabolism in Alzheimer’s disease. Eur J Nucl Med Mol Imaging 38:343-351
360. Zhang W, Oya S, Kung MP et al (2005a) F-18 polyethyleneglycol stilbenes as PET imaging agents targeting Abeta aggregates in the brain. Nucl Med Biol 32:799-809
361. Zhang W, Oya S, Kung MP et al (2005b) F-18 stilbenes as PET imaging agents for detecting beta- amyloid plaques in the brain. J Med Chem 48:5980-5988